{"title": "Revisi\u00f3n de estudios pre-cl\u00ednicos de candidatos a vacuna contra la malaria causada por Plasmodium falciparum", "author": "Anny Jineth Camargo Mancipe; Diana Diaz Ar\u00e9valo; David Ricardo Salamanca; Laura Esperanza Cuy Chaparro; Diego Fernando Camargo Mancipe", "url": null, "hostname": null, "description": "Introducci\u00f3n. La malaria es una enfermedad que causa aproximadamente 400.000 muertes al a\u00f1o, especialmente en ni\u00f1os menores de 5 a\u00f1os; la b\u00fasqueda de una vacuna eficaz y segura sigue siendo un reto para los investigadores, sin embargo, antes de iniciar los estudios de fase cl\u00ednica, los ensayos precl\u00ednicos en modelo animal deben brindar resultados de seguridad e inmunogenicidad que lleven a respuestas eficaces de protecci\u00f3n. Objetivo. Revisar las principales caracter\u00edsticas de la respuesta inmunol\u00f3gica y eficacia en estudios pre-cl\u00ednicos de candidatos a vacuna contra la malaria por Plasmodium falciparum. M\u00e9todos. Revisi\u00f3n descriptiva de los principales estudios precl\u00ednicos de candidatos a vacuna contra la malaria, basados en subunidades, par\u00e1sitos atenuados y vacunas multi-estadio, multi-epitope, que se han realizado para evaluar inmunogenicidad y eficacia en modelo animal. Esta revisi\u00f3n se llev\u00f3 a cabo a partir de la b\u00fasqueda de literatura en bases de datos electr\u00f3nicas especializadas en investigaci\u00f3n cient\u00edfica. Se encontraron 118 documentos, de los cuales se seleccionaron 91 y se excluyeron 17 por no cumplir con los criterios de inclusi\u00f3n, para un total de 74 referencias analizadas. Resultados. Muchos candidatos a vacuna contra la malaria causada por Plasmodium falciparum han reportado resultados prometedores contra cepas homologas, sin embargo, ante el reto con cepas heter\u00f3logas la eficacia disminuye, por otra parte, la respuesta inmune y protectiva duradera contin\u00faa siendo un objetivo clave, convirti\u00e9ndose en una prioridad. Conclusiones. Los estudios precl\u00ednicos en modelo animal son necesarios antes de avanzar a fases cl\u00ednicas, la evaluaci\u00f3n de inmunogenicidad y eficacia es un aspecto esencial para la evaluaci\u00f3n de candidatos a vacuna.", "sitename": "Revista Investigaci\u00f3n en Salud Universidad de Boyac\u00e1", "date": "2019-07-26", "id": null, "license": "CC BY-NC 4.0", "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Revisi\u00f3n de estudios pre-cl\u00ednicos de candidatos a vacuna contra la malaria causada por Plasmodium falciparum\nReview of preclinical studies of candidates for malaria vaccine caused by Plasmodium falciparum\nContenido principal del art\u00edculo\nResumen\nIntroducci\u00f3n. La malaria es una enfermedad que causa aproximadamente 400.000 muertes al a\u00f1o, especialmente en ni\u00f1os menores de 5 a\u00f1os; la b\u00fasqueda de una vacuna eficaz y segura sigue siendo un reto para los investigadores, sin embargo, antes de iniciar los estudios de fase cl\u00ednica, los ensayos precl\u00ednicos en modelo animal deben brindar resultados de seguridad e inmunogenicidad que lleven a respuestas eficaces de protecci\u00f3n. Objetivo. Revisar las principales caracter\u00edsticas de la respuesta inmunol\u00f3gica y eficacia en estudios pre-cl\u00ednicos de candidatos a vacuna contra la malaria por Plasmodium falciparum. M\u00e9todos. Revisi\u00f3n descriptiva de los principales estudios precl\u00ednicos de candidatos a vacuna contra la malaria, basados en subunidades, par\u00e1sitos atenuados y vacunas multi-estadio, multi-epitope, que se han realizado para evaluar inmunogenicidad y eficacia en modelo animal. Esta revisi\u00f3n se llev\u00f3 a cabo a partir de la b\u00fasqueda de literatura en bases de datos electr\u00f3nicas especializadas en investigaci\u00f3n cient\u00edfica. Se encontraron 118 documentos, de los cuales se seleccionaron 91 y se excluyeron 17 por no cumplir con los criterios de inclusi\u00f3n, para un total de 74 referencias analizadas. Resultados. Muchos candidatos a vacuna contra la malaria causada por Plasmodium falciparum han reportado resultados prometedores contra cepas homologas, sin embargo, ante el reto con cepas heter\u00f3logas la eficacia disminuye, por otra parte, la respuesta inmune y protectiva duradera contin\u00faa siendo un objetivo clave, convirti\u00e9ndose en una prioridad. Conclusiones. Los estudios precl\u00ednicos en modelo animal son necesarios antes de avanzar a fases cl\u00ednicas, la evaluaci\u00f3n de inmunogenicidad y eficacia es un aspecto esencial para la evaluaci\u00f3n de candidatos a vacuna.\nPalabras clave:\nDescargas\nDetalles del art\u00edculo\nReferencias (VER)\nDraper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria Vaccines: Recent Advances and New Horizons. Cell Host Microbe. 2018;24:43-56.\n[https://doi.org/10.1016/j.chom.2018.06.008](https://doi.org/10.1016/j.chom.2018.06.008)\nMiller LH, Ackerman HC, Su X, Wellems TE. Malaria biology and disease pathogenesis: insights for new treatments. Nat Med. 2013;19:156-67.\n[https://doi.org/10.1038/nm.3073](https://doi.org/10.1038/nm.3073)\nHowes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95(6 Suppl):15-34.\n[https://doi.org/10.4269/ajtmh.16-0141](https://doi.org/10.4269/ajtmh.16-0141)\nPhillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis WC, Wells TNC. Malaria. Nat Rev Dis Primer. 2017;3:23.\n[https://doi.org/10.1038/nrdp.2017.50](https://doi.org/10.1038/nrdp.2017.50)\nCowman AF, Tonkin CJ, Tham W-H, Duraisingh MT. The Molecular Basis of Erythrocyte Invasion by Malaria Parasites. Cell Host Microbe. 2017;22(2):232-245.\n[https://doi.org/10.1016/j.chom.2017.07.003](https://doi.org/10.1016/j.chom.2017.07.003)\nPatarroyo ME, Alba MP, Rojas-Luna R, Berm\u00fadez A, Aza-Conde J. Functionally relevant proteins in Plasmodium falciparum host cell invasion. Immunotherapy. 2017;9:131-55.\n[https://doi.org/10.2217/imt-2016-0091](https://doi.org/10.2217/imt-2016-0091)\nPatarroyo ME, Berm\u00fadez A, Patarroyo MA. Structural and Immunological Principles Leading to Chemically Synthesized, Multiantigenic, Multistage, Minimal Subunit-Based Vaccine Development. Chem Rev. 2011;111(5):3459-507.\n[https://doi.org/10.1021/cr100223m](https://doi.org/10.1021/cr100223m)\nWorld Health Organization. World malaria report 2018. 2018; 1-210 p.\nWorld Health Organization, World Health Organization, Global Malaria Programme. Global technical strategy for malaria, 2016-2030. World Health Organization; 2015. 1-35 p.\nGoh YS. Mcguire D, Renia L.Vaccination With Sporozoites: Models and Correlates of Protection. Front Immunol. 2019;10:18.\n[https://doi.org/10.3389/fimmu.2019.01227](https://doi.org/10.3389/fimmu.2019.01227)\nDe SL, Stanisic DI, van Breda K, Bellete B, Harris I, McCallum F, et al. Persistence and immunogenicity of chemically attenuated blood stage Plasmodium falciparum in Aotus monkeys. Int J Parasitol. 2016;46:581-91.\n[https://doi.org/10.1016/j.ijpara.2016.05.002](https://doi.org/10.1016/j.ijpara.2016.05.002)\nHerrera S, Perlaza BL, Bonelo A, Ar\u00e9valo-Herrera M. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol. 2002;32(13):1625-35.\n[https://doi.org/10.1016/s0020-7519(02)00191-1](https://doi.org/10.1016/s0020-7519(02)00191-1)\nLanghorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D, et al. The relevance of non-human primate and rodent malaria models for humans. Malar J. 2011;10:1-23.\n[https://doi.org/10.1186/1475-2875-10-23](https://doi.org/10.1186/1475-2875-10-23)\nNino-Vasquez JJ, Vogel D, Rodr\u00edguez R, Moreno A, Patarroyo ME, Pluschke G, et al. Sequence and diversity of DRB genes of Aotus nancymaae , a primate model for human malaria parasites. Immunogenetics. 2000;51(3):219-30.\n[https://doi.org/10.1007/s002510050035](https://doi.org/10.1007/s002510050035)\nSu\u00e1rez M. CF, Patarroyo MA, Patarroyo ME. Characterisation and comparative analysis of MHC-DPA1 exon 2 in the owl monkey (Aotus nancymaae). Gene.2011;470(1-2):37-45.\n[https://doi.org/10.1016/j.gene.2010.09.006](https://doi.org/10.1016/j.gene.2010.09.006)\nCardenas PP, Su\u00e1rez CF, Mart\u00ednez P, Patarroyo ME, Patarroyo MA. MHC class I genes in the owl monkey: mosaic organisation, convergence and loci diversity. Immunogenetics. 2005;56(11):818-32.\n[https://doi.org/10.1007/s00251-004-0751-5](https://doi.org/10.1007/s00251-004-0751-5)\nBaquero JE, Miranda S, Murillo O, Mateus H, Trujillo E, Su\u00e1rez C, et al. Reference strand conformational analysis (RSCA) is a valuable tool in identifying MHC-DRB sequences in three species of Aotus monkeys. Immunogenetics. 2006;58(7):590-7.\n[https://doi.org/10.1007/s00251-006-0101-x](https://doi.org/10.1007/s00251-006-0101-x)\nGuerrero JE, Pacheco DP, Su\u00e1rez CF, Mart\u00ednez P, Aristizabal F, Moncada CA, et al. Characterizing T-cell receptor gamma-variable gene in Aotus nancymaae owl monkey peripheral blood. Tissue Antigens.2003;62(6):472-82.\n[https://doi.org/10.1046/j.1399-0039.2003.00130.x](https://doi.org/10.1046/j.1399-0039.2003.00130.x)\nJones TR, Obaldia N, Hoffman SL, Gramzinski RA. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg. 2000;62(6):675-80.\n[https://doi.org/10.4269/ajtmh.2000.62.675](https://doi.org/10.4269/ajtmh.2000.62.675)\nSu\u00e1rez CF, Pab\u00f3n L, Barrera A, Aza-Conde J, Patarroyo MA, Patarroyo ME. Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans. Biochem Biophys Res Commun. 2017;491(4):1062-9.\n[https://doi.org/10.1016/j.bbrc.2017.08.012](https://doi.org/10.1016/j.bbrc.2017.08.012)\nMinkah NK, Schafer C, Kappe SHI. Humanized Mouse Models for the Study of Human Malaria Parasite Biology, Pathogenesis, and Immunity. Front Immunol. 2018;1-9.\n[https://doi.org/10.3389/fimmu.2018.00807](https://doi.org/10.3389/fimmu.2018.00807)\nNussenzweig RS, Vanderberg J, Most H, Orton C. Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei. Nature. 1967;216:160-2.\n[https://doi.org/10.1038/216160a0](https://doi.org/10.1038/216160a0)\nNussenzweig RS, Vanderberg JP, Most H, Orton C. Specificity of Protective Immunity produced by X-irradiated Plasmodium berghei Sporozoites. Nature.1969;222(5192):488-9.\n[https://doi.org/10.1038/222488a0](https://doi.org/10.1038/222488a0)\nVanderberg JP, Nussenzweig RS, Most H, Orton CG. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. II. Effects of radiation on sporozoites. J Parasitol. 1968;54(6):1175-80.\n[https://doi.org/10.2307/3276987](https://doi.org/10.2307/3276987)\nNussenzweig RS, Zavala F. A Malaria Vaccine Based on a Sporozoite Antigen.NEngl J Med.1997;336(2):128-30.\n[https://doi.org/10.1056/NEJM199701093360210](https://doi.org/10.1056/NEJM199701093360210)\nNussenzweig V, Nussenzweig RS. Rationale for the Development of an Engineered Sporozoite Malaria Vaccine. Adv Immunol.1989;45:283-334.\n[https://doi.org/10.1016/s0065-2776(08)60695-1](https://doi.org/10.1016/s0065-2776(08)60695-1)\nEpstein JE, Tewari K, Lyke KE, Sim BKL, Billingsley PF, Laurens MB, et al. Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity. Science. 2011;334(6055):475-80.\n[https://doi.org/10.1126/science.1211548](https://doi.org/10.1126/science.1211548)\nHill AV, Biswas S, Draper S, Rampling T, Reyes-Sandoval A. Towards a multi-antigen multi-stage malaria vaccine. Malar J. 2014;13(S1):O31. .\n[https://doi.org/10.1186/1475-2875-13-S1-O31](https://doi.org/10.1186/1475-2875-13-S1-O31)\nTolia NH, Enemark EJ, Sim BKL, Joshua-Tor L. Structural Basis for the EBA-175 Erythrocyte Invasion Pathway of the Malaria Parasite Plasmodium falciparum. Cell. 2005;122(2):183-93.\n[https://doi.org/10.1016/j.cell.2005.05.033](https://doi.org/10.1016/j.cell.2005.05.033)\nSim BKL, Chitnis CE, Wasniowska K, Millert LH. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. 1994;264:1941-3.\n[https://doi.org/10.1126/science.8009226](https://doi.org/10.1126/science.8009226)\nJones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, Liang H, et al. Protection of Aotus Monkeys by Plasmodium falciparum EBA\u2010175 Region II DNA Prime\u2013Protein Boost Immunization Regimen. J Infect Dis. 2001;183(2):303-12.\n[https://doi.org/10.1086/317933](https://doi.org/10.1086/317933)\nVolz JC, Yap A, Sisquella X, Thompson JK, Lim NTY, Whitehead LW, et al. Essential Role of the PfRh5/PfRipr/CyRPA Complex during Plasmodium falciparum Invasion of Erythrocytes. Cell Host Microbe. 2016;20:60-71.\n[https://doi.org/10.1016/j.chom.2016.06.004](https://doi.org/10.1016/j.chom.2016.06.004)\nTran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang C-Y, et al. Naturally Acquired Antibodies Specific for Plasmodium falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection From Malaria. J Infect Dis. 2014;209:789-98.\n[https://doi.org/10.1093/infdis/jit553](https://doi.org/10.1093/infdis/jit553)\nPatel SD, Ahouidi AD, Bei AK, Dieye TN, Mboup S, Harrison SC, et al. Plasmodium falciparum Merozoite Surface Antigen, PfRH5, Elicits Detectable Levels of Invasion-Inhibiting Antibodies in Humans. J Infect Dis. 2013;208:1679-87.\n[https://doi.org/10.1093/infdis/jit385](https://doi.org/10.1093/infdis/jit385)\nChen L, Xu Y, Healer J, Thompson JK, Smith BJ, Lawrence MC, et al. Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes. eLife. 2014;3:1-10.\n[https://doi.org/10.7554/eLife.04187.001](https://doi.org/10.7554/eLife.04187.001)\nSheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. ChAd63-MVA\u2013vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Mol Ther. 2012;20(12):2355-68.\n[https://doi.org/10.1038/mt.2012.223](https://doi.org/10.1038/mt.2012.223)\nDraper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008;14:819-21.\n[https://doi.org/10.1038/nm.1850](https://doi.org/10.1038/nm.1850)\nde Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P, et al. The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. J Immunol. 2011;187:2602-16.\n[https://doi.org/10.4049/jimmunol.1101004](https://doi.org/10.4049/jimmunol.1101004)\nDouglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ, et al. A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host Microbe. 2015;17:130-9.\n[https://doi.org/10.1016/j.chom.2014.11.017](https://doi.org/10.1016/j.chom.2014.11.017)\nSrinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc Natl Acad Sci. 2011;108:13275-80.\n[https://doi.org/10.1073/pnas.1110303108](https://doi.org/10.1073/pnas.1110303108)\nTyler JS, Boothroyd JC. The C-Terminus of Toxoplasma RON2 Provides the Crucial Link between AMA1 and the Host-Associated Invasion Complex. Soldati-Favre D, editor. PLoS Pathog. 2011;7:1-12.\n[https://doi.org/10.1371/journal.ppat.1001282](https://doi.org/10.1371/journal.ppat.1001282)\nMital J, Meissner M, Soldati D, Ward GE. Conditional Expression of Toxoplasma gondii Apical Membrane Antigen-1 (TgAMA1) Demonstrates That TgAMA1 Plays a Critical Role in Host Cell Invasion. Mol Biol Cell. 2005;16(9):4341-9.\n[https://doi.org/10.1091/mbc.e05-04-0281](https://doi.org/10.1091/mbc.e05-04-0281)\nPayne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, et al. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. J Infect Dis. 2016;213:1743-51.\n[https://doi.org/10.1093/infdis/jiw039](https://doi.org/10.1093/infdis/jiw039)\nSpring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A. Beeson JG, editor. PLoS ONE. 2009;4(4):1-13.\n[https://doi.org/10.1371/journal.pone.0005254](https://doi.org/10.1371/journal.pone.0005254)\nSrinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, et al. A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. Npj Vaccines. 2017;2(1):1-10.\n[https://doi.org/10.1038/s41541-017-0015-7](https://doi.org/10.1038/s41541-017-0015-7)\nBurns JM, Miura K, Sullivan J, Long CA, Barnwell JW. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Malar J. 2016;1-7.\n[https://doi.org/10.1186/s12936-016-1226-5](https://doi.org/10.1186/s12936-016-1226-5)\nBejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. N Engl J Med. 2008;359:2521-32.\n[https://doi.org/10.1056/NEJMoa0807381](https://doi.org/10.1056/NEJMoa0807381)\nBrian Greenwood. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet. 2015;386:60721-8.\n[https://doi.org/10.1016/S0140-6736(15)60721-8](https://doi.org/10.1016/S0140-6736(15)60721-8)\nVekemans J, Leach A, Cohen J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine. 2009;27:67-71.\n[https://doi.org/10.1016/j.vaccine.2009.10.013](https://doi.org/10.1016/j.vaccine.2009.10.013)\nCohen J, Nussenzweig V, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum Vaccin. 2010;6:90-6.\n[https://doi.org/10.4161/hv.6.1.9677](https://doi.org/10.4161/hv.6.1.9677)\nPichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, et al. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine. 2009;28(2):452-62.\n[https://doi.org/10.1016/j.vaccine.2009.10.022](https://doi.org/10.1016/j.vaccine.2009.10.022)\nKester KE, Stewart AV, Walsh DS, Voss G, Tongtawe P, Ballou WR, et al. Safety and immunogenicity of RTS,S + TRAP malaria vaccine, formulated in the AS02A adjuvant system, in infant Rhesus monkeys. Am J Trop Med Hyg. 2004;70:499-509.\n[https://doi.org/10.4269/ajtmh.2004.70.499](https://doi.org/10.4269/ajtmh.2004.70.499)\nKester KE, Cummings JF, Ofori\u2010Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, Double\u2010Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria\u2010Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection. J Infect Dis. 2009;200:337-46.\n[https://doi.org/10.1086/600120](https://doi.org/10.1086/600120)\nGar\u00e7on N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6:723-39.\n[https://doi.org/10.1586/14760584.6.5.723](https://doi.org/10.1586/14760584.6.5.723)\nWalsh D, Gettayacamin M, Leitner W, Lyon J, Stewart V, Marit G, et al. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A. Vaccine. 2006;24:4167-78.\n[https://doi.org/10.1016/j.vaccine.2006.02.041](https://doi.org/10.1016/j.vaccine.2006.02.041)\nStewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, et al. Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone. Infect Immun. 2007;75(5):2283-90.\n[https://doi.org/10.1128/IAI.01879-06](https://doi.org/10.1128/IAI.01879-06)\nDunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine. 2006;(15):2850-9. https://doi: 10.1016/j.vaccine.2005.12.041\nGwADz RW, Cochrane H, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ. 1979;165-73.\nHoffman SL, Goh LML, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of Humans against Malaria by Immunization with Radiation\u2010Attenuated Plasmodium falciparum Sporozoites. J Infect Dis. 2002;185:1155-64.\n[https://doi.org/10.1086/339409](https://doi.org/10.1086/339409)\nPatarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, Mart\u00ednez A et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature. 1987;328:629-32.\n[https://doi.org/10.1038/328629a0](https://doi.org/10.1038/328629a0)\nNoya G. O, Berti YG, Noya BA d., Borges R, Zerpa N, Urb ez JD, et al. A Population-Based Clinical Trial with the SPf66 Synthetic Plasmodium falciparum Malaria Vaccine in Venezuela. J Infect Dis. 1994;170:396-402.\n[https://doi.org/10.1093/infdis/170.2.396](https://doi.org/10.1093/infdis/170.2.396)\nSempertegui F, Estrella B, Moscoso J, Piedrahita L, Hern\u00e1ndez D, Gaybor J et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodiumfalciparum infection in a randomized double-blind placebo-controlled field trial fin an endemic area of Ecuador. Vaccine. 1994;337-42.\n[https://doi.org/10.1016/0264-410X(94)90098-1](https://doi.org/10.1016/0264-410X(94)90098-1)\nValero M, Amador R, Aponte J, Narvaez A, Galindo C, Silva Y et al. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine. 1996;14:1466-70.\n[https://doi.org/10.1016/S0264-410X(96)00070-9](https://doi.org/10.1016/S0264-410X(96)00070-9)\nValero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. The Lancet. 1993;341:705-10.\n[https://doi.org/10.1016/0140-6736(93)90483-W](https://doi.org/10.1016/0140-6736(93)90483-W)\nPatarroyo ME, Patarroyo MA. Emerging Rules for Subunit-Based, Multiantigenic, Multistage Chemically Synthesized Vaccines. Acc Chem Res. 2008;41:377-86.\n[https://doi.org/10.1021/ar700120t](https://doi.org/10.1021/ar700120t)\nVaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest. 2012;122:3618-28.\n[https://doi.org/10.1172/JCI62684](https://doi.org/10.1172/JCI62684)\nMikolajczak SA, Vaughan AM, Kangwanrangsan N, Roobsoong W, Fishbaugher M, Yimamnuaychok N, et al. Plasmodium vivax Liver Stage Development and Hypnozoite Persistence in Human Liver-Chimeric Mice. Cell Host Microbe. 2015;17(4):526-35.\n[https://doi.org/10.1016/j.chom.2015.02.011](https://doi.org/10.1016/j.chom.2015.02.011)\nSack BK, Mikolajczak SA, Fishbaugher M, Vaughan AM, Flannery EL, Nguyen T, et al. Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice. Npj Vaccines. 2017;2(1):1-11.\n[https://doi.org/10.1038/s41541-017-0028-2](https://doi.org/10.1038/s41541-017-0028-2)\nWeiss GE, Crabb BS, Gilson PR. Overlaying Molecular and Temporal Aspects of Malaria Parasite Invasion. Trends Parasitol. 2016;32(4):284-95.\n[https://doi.org/10.1016/j.pt.2015.12.007](https://doi.org/10.1016/j.pt.2015.12.007)\nWeiss GE, Gilson PR, Taechalertpaisarn T, Tham W-H, de Jong NWM, Harvey KL, et al. Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes. Blackman MJ, editor. PLOS Pathog. 2015;11(2):e1004670.\n[https://doi.org/10.1371/journal.ppat.1004670](https://doi.org/10.1371/journal.ppat.1004670)\nMoser KA, Dr\u00e1bek EF, Dwivedi A, Crabtree J, Stucke EM, Dara A, et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genomics; 2019\n[https://doi.org/10.1101/684175](https://doi.org/10.1101/684175)\nLyke KE, Fern\u00e1ndez-Vi\u0148a MA, Cao K, Hollenbach J, Coulibaly D, Kone AK, et al. Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens. 2011;77(6):562-71.\n[https://doi.org/10.1111/j.1399-0039.2011.01661.x](https://doi.org/10.1111/j.1399-0039.2011.01661.x)\nMatern BM, Olieslagers TI, Voorter CEM, Groeneweg M, Tilanus MGJ. Insights into the polymorphism in HLA\u2010DRA and its evolutionary relationship with HLA Haplotypes. HLA. 2019;95(2):13730.\n[https://doi.org/10.1111/tan.13730](https://doi.org/10.1111/tan.13730)\nLa Gruta NL, Gras S, Daley SR, Thomas PG, Rossjohn J. Understanding the drivers of MHC restriction of T cell receptors. Nat Rev Immunol.2018;18(7):467-78.\n[https://doi.org/10.1038/](https://doi.org/10.1038/) s41577-018-0007-5", "language": null, "image": "https://revistasdigitales.uniboyaca.edu.co/public/journals/3/cover_issue_43_es_ES.png", "pagetype": null, "links": ["#main-navigation", "#main-content", "#sidebar", "/index.php/", null, "#", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/user/setLocale/en_US", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/user/setLocale/pt_PT", "https://doi.org/10.24267/issn.2389-7325", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/user/register", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/login", "\t\t\t\t\t\t\thttps://revistasdigitales.uniboyaca.edu.co/index.php/rs/index\n\t\t\t\t\t\t", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/index", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/current", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/archive", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/announcement", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/about", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/about", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/about/submissions", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/about/editorialTeam", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/about/contact", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/about/privacy", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/pr", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/search/search", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/index", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/archive", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/view/43", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/view/43", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/353/494", "//revistasdigitales.uniboyaca.edu.co/flip/index.php?pdf=https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/download/353/494", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/citationstylelanguage/get/apa?submissionId=353&publicationId=309", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/citationstylelanguage/get/chicago-author-date?submissionId=353&publicationId=309", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/citationstylelanguage/get/ieee?submissionId=353&publicationId=309", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/citationstylelanguage/get/modern-language-association?submissionId=353&publicationId=309", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/citationstylelanguage/get/vancouver?submissionId=353&publicationId=309", "https://doi.org/10.24267/23897325.353", "https://plu.mx/plum/a/?doi=10.24267/23897325.353", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/view/43", "https://creativecommons.org/licenses/by-nc/4.0/", "https://creativecommons.org/licenses/by-nc/4.0/", "https://orcid.org/0000-0003-3766-5500", "https://orcid.org/0000-0002-2234-7078", "https://orcid.org/0000-0002-2016-2117", "https://orcid.org/0000-0003-0991-0302", "//revistasdigitales.uniboyaca.edu.co/index.php/rs/search/search?query=malaria", "https://scholar.google.es/scholar?hl=es&as_sdt=0%2C5&q=malaria&oqmalaria", "https://www.metarevistas.org/Search/Results?lookfor=malaria&type=AllFields&limit=20&sort=relevance", "//revistasdigitales.uniboyaca.edu.co/index.php/rs/search/search?query=vacunas", "https://scholar.google.es/scholar?hl=es&as_sdt=0%2C5&q=vacunas&oqvacunas", "https://www.metarevistas.org/Search/Results?lookfor=vacunas&type=AllFields&limit=20&sort=relevance", "//revistasdigitales.uniboyaca.edu.co/index.php/rs/search/search?query=inmunogenicidad vacunal", "https://scholar.google.es/scholar?hl=es&as_sdt=0%2C5&q=inmunogenicidad vacunal&oqinmunogenicidad vacunal", "https://www.metarevistas.org/Search/Results?lookfor=inmunogenicidad vacunal&type=AllFields&limit=20&sort=relevance", "//revistasdigitales.uniboyaca.edu.co/index.php/rs/search/search?query=Plasmodium falciparum", "https://scholar.google.es/scholar?hl=es&as_sdt=0%2C5&q=Plasmodium falciparum&oqPlasmodium falciparum", "https://www.metarevistas.org/Search/Results?lookfor=Plasmodium falciparum&type=AllFields&limit=20&sort=relevance", "//revistasdigitales.uniboyaca.edu.co/index.php/rs/search/search?query=eficacia", "https://scholar.google.es/scholar?hl=es&as_sdt=0%2C5&q=eficacia&oqeficacia", "https://www.metarevistas.org/Search/Results?lookfor=eficacia&type=AllFields&limit=20&sort=relevance", "//revistasdigitales.uniboyaca.edu.co/index.php/rs/search/search?query=experimentaci\u00f3n animal", "https://scholar.google.es/scholar?hl=es&as_sdt=0%2C5&q=experimentaci\u00f3n animal&oqexperimentaci\u00f3n animal", "https://www.metarevistas.org/Search/Results?lookfor=experimentaci\u00f3n animal&type=AllFields&limit=20&sort=relevance", "https://doi.org/10.1016/j.chom.2018.06.008", "https://doi.org/10.1038/nm.3073", "https://doi.org/10.4269/ajtmh.16-0141", "https://doi.org/10.1038/nrdp.2017.50", "https://doi.org/10.1016/j.chom.2017.07.003", "https://doi.org/10.2217/imt-2016-0091", "https://doi.org/10.1021/cr100223m", "https://doi.org/10.3389/fimmu.2019.01227", "https://doi.org/10.1016/j.ijpara.2016.05.002", "https://doi.org/10.1016/s0020-7519(02)00191-1", "https://doi.org/10.1186/1475-2875-10-23", "https://doi.org/10.1007/s002510050035", "https://doi.org/10.1016/j.gene.2010.09.006", "https://doi.org/10.1007/s00251-004-0751-5", "https://doi.org/10.1007/s00251-006-0101-x", "https://doi.org/10.1046/j.1399-0039.2003.00130.x", "https://doi.org/10.4269/ajtmh.2000.62.675", "https://doi.org/10.1016/j.bbrc.2017.08.012", "https://doi.org/10.3389/fimmu.2018.00807", "https://doi.org/10.1038/216160a0", "https://doi.org/10.1038/222488a0", "https://doi.org/10.2307/3276987", "https://doi.org/10.1056/NEJM199701093360210", "https://doi.org/10.1016/s0065-2776(08)60695-1", "https://doi.org/10.1126/science.1211548", "https://doi.org/10.1186/1475-2875-13-S1-O31", "https://doi.org/10.1016/j.cell.2005.05.033", "https://doi.org/10.1126/science.8009226", "https://doi.org/10.1086/317933", "https://doi.org/10.1016/j.chom.2016.06.004", "https://doi.org/10.1093/infdis/jit553", "https://doi.org/10.1093/infdis/jit385", "https://doi.org/10.7554/eLife.04187.001", "https://doi.org/10.1038/mt.2012.223", "https://doi.org/10.1038/nm.1850", "https://doi.org/10.4049/jimmunol.1101004", "https://doi.org/10.1016/j.chom.2014.11.017", "https://doi.org/10.1073/pnas.1110303108", "https://doi.org/10.1371/journal.ppat.1001282", "https://doi.org/10.1091/mbc.e05-04-0281", "https://doi.org/10.1093/infdis/jiw039", "https://doi.org/10.1371/journal.pone.0005254", "https://doi.org/10.1038/s41541-017-0015-7", "https://doi.org/10.1186/s12936-016-1226-5", "https://doi.org/10.1056/NEJMoa0807381", "https://doi.org/10.1016/S0140-6736(15)60721-8", "https://doi.org/10.1016/j.vaccine.2009.10.013", "https://doi.org/10.4161/hv.6.1.9677", "https://doi.org/10.1016/j.vaccine.2009.10.022", "https://doi.org/10.4269/ajtmh.2004.70.499", "https://doi.org/10.1086/600120", "https://doi.org/10.1586/14760584.6.5.723", "https://doi.org/10.1016/j.vaccine.2006.02.041", "https://doi.org/10.1128/IAI.01879-06", "https://doi.org/10.1086/339409", "https://doi.org/10.1038/328629a0", "https://doi.org/10.1093/infdis/170.2.396", "https://doi.org/10.1016/0264-410X(94)90098-1", "https://doi.org/10.1016/S0264-410X(96)00070-9", "https://doi.org/10.1016/0140-6736(93)90483-W", "https://doi.org/10.1021/ar700120t", "https://doi.org/10.1172/JCI62684", "https://doi.org/10.1016/j.chom.2015.02.011", "https://doi.org/10.1038/s41541-017-0028-2", "https://doi.org/10.1016/j.pt.2015.12.007", "https://doi.org/10.1371/journal.ppat.1004670", "https://doi.org/10.1101/684175", "https://doi.org/10.1111/j.1399-0039.2011.01661.x", "https://doi.org/10.1111/tan.13730", "https://doi.org/10.1038/", "https://scholar.google.com/scholar?q=10.24267/23897325.353", "http://europepmc.org/search?scope=fulltext&query=(REF:10.24267/23897325.353)", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/349", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/view/43", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/498", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/view/49", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/373", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/view/45", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/473", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/issue/view/49", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/about/submissions", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/announcement/view/17", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/announcement/view/14", "https://www.youtube.com/watch?v=nU5LMSiSet0", "https://youtu.be/Nc8ilH1QEBU", "/index.php/rs/about#tipolo", "/index.php/rs/about#procedimiento", "/index.php/rs/about#openaccess", "/index.php/rs/about#deposito", "/index.php/rs/about#declaration", "/index.php/rs/about#politicaeva", "/index.php/rs/about#normascomite", "/index.php/rs/about#plagio", "/index.php/rs/about#conflicto", "/index.php/rs/about#sanciones", "/index.php/rs/about#politicacobro", "/index.php/rs/about#frequency", "https://reseau-mirabel.info/", "https://www.redib.org/Serials/Record/oai_revista3453-revista-investigaci%C3%B3n-en-salud-universidad-de-boyac%C3%A1", "http://portal.revistas.bvs.br/index.php?issn=2389-7325&lang=es", null, " ", "http://www.fundacionindex.com/bibliometria/bresumen.php?id=477", "http://www.latindex.org/latindex/ficha?folio=26435", "https://scholar.google.com/citations?user=8S8bGJoAAAAJ&hl=es", " ", " ", " ", "https://drive.google.com/open?id=0B5ID4ubDJM6tVi0yamYtNGlLLThidmVuUnQ5RWV5TlYwdEVR", "https://drive.google.com/open?id=0B5ID4ubDJM6tUzF5V3U4ZDdjRks3Q2RVT0hSNDlYaUVTWl9r", "https://drive.google.com/open?id=0B5ID4ubDJM6tYllVQVBvY2VaQ1ktR2hLcXdMUkRhQzZuZjd3", "/public/site/images/pie/Indicaciones a los autores.pdf", "https://twitter.com/RUniboyaca", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/553", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/266", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/128", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/746", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/498", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/gateway/plugin/WebFeedGatewayPlugin/atom", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/gateway/plugin/WebFeedGatewayPlugin/rss2", "https://revistasdigitales.uniboyaca.edu.co/index.php/rs/gateway/plugin/WebFeedGatewayPlugin/rss", "/es/tunja", "/es/sogamoso", "/es/yopal", "https://www.uniboyaca.edu.co/es/transparencia-e-informacion-al-ciudadano", "https://www.uniboyaca.edu.co/es/micrositio/nuestros-canales-de-atencion", "https://www.uniboyaca.edu.co/directory#org/1049", "https://www.uniboyaca.edu.co/es/preguntas-frecuentes/sesion/preguntas_frecuentes_admisiones", "mailto:habeasdata@uniboyaca.edu.co", "mailto:notificacionesjudiciales@uniboyaca.edu.co", "/mapa-del-sitio", "/user/login", "https://www.uniboyaca.edu.co/sites/default/files/2019-02/Proteccio%CC%81n%20de%20Datos%20-Acuerdo%201155%20-%202018.pdf", "https://www.uniboyaca.edu.co/sites/default/files/2020-10/Derechos%20Pecunarios%20an%CC%83o%202021.pdf", "http://www.uniboyaca.edu.co/sites/default/files/2018-01/Reglamento%20Bienestar%20Universitario.pdf", "http://www.uniboyaca.edu.co/sites/default/files/2018-01/Estatuto%20General.pdf", "/es/node/4053", "/es/node/2219", "/es/regimen-tributario-especial", "https://www.metabiblioteca.com/"]}